Form 4 for WST West Pharmaceutical Services
Accepted 2023-05-11 00:00:00 ET · period of report 2023-05-09 · accession 0001562180-23-004067 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-11 | 2023-05-09 | WST | Green Eric Mark | Pres, CEO, Dir | S - Sale+OE | $363.11 | -44.0K | 135.1K | -25% | -$15.98M |
| D | 2023-05-11 | 2023-05-09 | WST | Green Eric Mark | Pres, CEO, Dir | M - OptEx | $57.38 | +50.0K | 178.6K | +39% | +$2.87M |
| D | 2023-05-11 | 2023-05-09 | WST | Green Eric Mark | Pres, CEO, Dir | M - OptEx | $0.00 | -50.0K | 148.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-09 | S | D | 14,157 | $361.95 | 164,417.09 | D | — | — | (F2) This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. (F3) The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $361.42 to $362.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| 2 | Common | Common Stock | 2023-05-09 | M | A | 50,000 | $57.38 | 178,574.09 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022. |
| 3 | Common | Common Stock | 2023-05-09 | S | D | 500 | $365.46 | 134,574.09 | D | — | — | (F2) This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. (F7) The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $365.43 to $365.48, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| 4 | Common | Common Stock | 2023-05-09 | S | D | 12,562 | $362.93 | 151,855.09 | D | — | — | (F2) This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. (F4) The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $362.42 to $363.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| 5 | Common | Common Stock | 2023-05-09 | S | D | 12,648 | $363.94 | 139,207.09 | D | — | — | (F2) This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. (F5) The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $363.42 to $364.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| 6 | Common | Common Stock | 2023-05-09 | S | D | 4,133 | $364.76 | 135,074.09 | D | — | — | (F2) This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person. (F6) The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $364.425 to $365.295, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-05-09 | M | D | 50,000 | $0.00 | 148,132 | D | $57.38 · — to 2025-04-24 | 50,000 Common Stock | (F8) This option is fully vested. |